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Summary
 
Lipoxins are bioactive eicosanoids that are immunomodulators. In human myeloid cells, lipoxin
(LX) A
 
4
 
 actions are mediated by interaction with a G protein–coupled receptor. To explore
functions of LXA
 
4
 
 and aspirin-triggered 5(
 
S
 
),6(
 
R
 
),15(
 
R
 
)-trihydroxy-7,9,13-
 
trans
 
-11-
 
cis
 
–eico-
satetraenoic acid (15-epi-LXA
 
4
 
) in vivo, we cloned and characterized a mouse LXA
 
4
 
 receptor
(LXA
 
4
 
R). When expressed in Chinese hamster ovary cells, the mouse LXA
 
4
 
R showed specific
binding to [
 
3
 
H]LXA
 
4 
 
(
 
K
 
d
 
 
 
ø
 
 1.5 nM), and with LXA
 
4 
 
activated GTP hydrolysis. Mouse
LXA
 
4
 
R mRNA was most abundant in neutrophils. In addition to LXA
 
4
 
 and 15-epi-LXA
 
4
 
,
bioactive LX stable analogues competed with both [
 
3
 
H]LXA
 
4
 
 and [
 
3
 
H]leukotriene D
 
4
 
 (LTD
 
4
 
)–
specific binding in vitro to neutrophils and endothelial cells, respectively. Topical application
of LXA
 
4
 
 analogues and novel aspirin-triggered 15-epi-LXA
 
4
 
 stable analogues to mouse ears
markedly inhibited neutrophil infiltration in vivo as assessed by both light microscopy and re-
duced myeloperoxidase activity in skin biopsies. The 15(
 
R
 
)-16-phenoxy-17,18, 19,20-tetranor-
LXA
 
4 
 
methyl ester (15-epi-16-phenoxy-LXA
 
4
 
), an analogue of aspirin triggered 15-epi-LXA
 
4
 
, and
15(
 
S
 
)-16-phenoxy-17,18,19,20-tetranor-LXA
 
4
 
 methyl ester (16-phenoxy-LXA
 
4
 
) were each as
potent as equimolar applications of the anti-inflammatory, dexamethasone. Thus, we identified
murine LXA
 
4
 
R, which is highly expressed on murine neutrophils, and showed that both LXA
 
4
 
and 15-epi-LXA
 
4
 
 stable analogues inhibit neutrophil infiltration in the mouse ear model of in-
flammation. These findings provide direct in vivo evidence for an anti-inflammatory action for
both aspirin-triggered LXA
 
4
 
 and LXA
 
4
 
 stable analogues and their site of action in vivo
 
.
 
L
 
ipoxins are trihydroxytetraene-containing eicosanoids
that are generated within vascular lumen by platelet-
leukocyte interactions and transcellular biosynthetic pathways
during multicellular responses such as inflammation, athero-
sclerosis, and thrombosis (as reviewed in reference 1). This
branch of the eicosanoid cascade generates specific tetraene-
containing products that appear to function as stop signals.
In this regard, lipoxins display selective actions on human
leukocytes in vitro that include inhibition of (
 
a
 
) FMLP and
leukotriene B
 
4
 
 (LTB
 
4
 
)
 
1
 
-induced neutrophil chemotaxis (2),
(
 
b
 
) FMLP-induced neutrophil transmigration through epi-
thelial cells
 
 
 
(3), and (
 
c
 
) neutrophil adhesion and transmigra-
tion with endothelial cells
 
 
 
(4). We have recently shown that
these actions of lipoxin (LX) A
 
4
 
; 5(
 
S
 
),6(
 
R
 
),15(
 
S
 
)-trihydroxy-
7,9,13-
 
trans
 
-11-
 
cis
 
-eicosatetraenoic acid are mediated via
signal transduction events initiated by engagement of high-
affinity G protein–coupled receptors in human cells
 
 
 
(4–6).
This includes LXA
 
4
 
-induced downregulation of CD11b/
CD18 in human neutrophils (5), an adhesion molecule that
plays an important role in endothelial–leukocyte interactions
(7). Although lipoxins do not directly inhibit the generation
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of reactive oxygen species by activated neutrophils (re-
viewed in reference 8), the ability of LX to block endothe-
lial cell–leukocyte interactions (4) can also prevent injury
initiated by leukocyte-derived reactive oxidants (9, 10).
Taken together, these results suggest that lipoxins play im-
portant regulatory roles in leukocyte trafficking and inflam-
mation.
The biosynthesis of lipoxins is initiated through cell–cell
and lipoxygenase (LO) interactions that are regulated by
specific cytokines
 
 
 
(1). One major pathway is mounted during
PMN–platelet interaction and involves both the 5-LO and
12-LO, and the other involves interactions between the
5-LO and 15-LO (recently reviewed in reference 8) that
are controlled by the cytokines IL-4 and IL-13 (11). Given
the wide use of aspirin, the mechanism of aspirin’s benefi-
cial actions in inflammation remains a topic of intense in-
terest. Aspirin has no direct impact on the lipoxygenases
(8). In this regard, a third major pathway for lipoxin bio-
synthesis was recently uncovered, which involves prosta-
glandin H synthase-II (PGHS-II) in endothelial cells and
5-LO in leukocytes that generate novel 15-epi-lipoxins
when PGHS-II is acetylated after treatment with aspirin (12).
The aspirin-triggered lipoxins, for example, 5(
 
S
 
),6(
 
R
 
),15(
 
R
 
)-
trihydroxy-7,9,13-
 
trans
 
-11-
 
cis
 
-eicosatetraenoic acid (15-epi-
LXA
 
4
 
), carries its C-15 alcohol in the R configuration, in-
stead of S as in native LXA4, and has potent inhibitory actions
in neutrophil adhesion, and 15-epi-LXB4 blocks cell prolif-
eration in vitro (12, 13). This pathway that leads to 15-epi-
LXA4 may mediate, in part, some of the beneficial actions
of aspirin.
Lipoxins are also generated in vivo in humans and in ex-
perimental animals (reviewed in reference 8). LXA4 and LXB4
are both formed in ischemic rat brain (14), and LXA4 is
generated in mouse kidneys with glomerulonephritis in a
P-selectin–dependent fashion predominantly via interactions
between platelets and neutrophils (15). In rats, the infiltra-
tion of neutrophils to glomerulonephritic kidneys is mark-
edly inhibited by prior exposure of neutrophils to LXA4 (16).
Also, LXA4 has recently been found to regulate LTB4-
mediated delayed hypersensitive reactions in guinea pig (17).
The actions of LXA4 are not mediated by competition at
the LTB4 receptor (18), but LXA4 is reported to antagonize
the formation of intracellular signals such as IP3 (19). In ad-
dition to its selective actions with leukocytes, LXA4 also
modulates the vasoconstrictor actions of leukotriene D4
(LTD4) in renal hemodynamics and is vasodilatory (20).
These actions of LXA4 are mediated by a receptor distinct
from that of the myeloid LXA4R and are consistent with
LXA4 acting on a subtype of the peptido-leukotriene recep-
tors, competing for LTC4 and LTD4 high-affinity sites that
are present on both mesangial (20) and endothelial cells
(21). Interest in the actions of LXA4 is also heightened by
findings with human subjects that indicate that LXA4 ad-
ministration via inhalation significantly blocks airway con-
striction in asthmatic subjects (22).
To explore biological functions of both lipoxins and the
recently identified aspirin-triggered lipoxins in vivo, it is
essential to identify the molecular basis of their response in
experimental animals. To this end, we report here isolation
of the mouse lipoxin A4 receptor (LXA4R) and that stable
analogues of LXA4 and the aspirin-triggered 15-epi-LXA4
that specifically compete at this site are potent inhibitors of
acute neutrophil infiltration in vivo.
Materials and Methods
Materials. Tritiated LXA4 ([11,12-3H]LXA4; z40 Ci/mmol) was
obtained by custom catalytic hydrogenation of 11,12-acetylenic-
LXA4 methyl ester that was supplied to and performed at Du Pont
New England Nuclear (Boston, MA), and the labeled LXA4 was puri-
fied as in Fiore et al. (18). a-[32P]dCTP (3,000 Ci/mmol) and g-[32P]
GTP (30 Ci/mmol) were purchased from Du Pont NEN. LXA4
synthetic analogues, 15-epi-LXA4-methyl ester, 5(S),6(R),15(R/S)-
trihydroxy-15-methyl-7,9,13-trans-11-cis-eicosatetraenoic acid (15
[R/S]-methyl-LXA4) methyl ester, and 16-phenoxy-17,18,19,20-
tetranor-LXA4-methyl ester, were prepared, isolated and analyzed
as described (23). 15(R)-16-phenoxy-17,18,19,20-tetranor-LXA4
methyl ester (15-epi-16-phenoxy-LXA4) and 15(R/S)-16-phe-
noxy-11,12-acetylenic-17,18,19,20-tetranor-LXA4 methyl ester
(15[R/S]-16-phenoxy-11,12-acetylenic-LXA4) as methyl esters
were designed from knowledge of 15-epi-LXA4 structure and
bioactivities (12) and were separated and isolated by RP-HPLC,
and their identities were confirmed by NMR. Synthetic LXB4,
LTB4, and LTD4 were obtained from Cascade Biochem Ltd.
(Reading,  Berkshire, England). SKF-104353 was a gift from Smith
Kline and French Laboratories (King of Prussia, PA). Dulbecco’s
phosphate-buffered saline (DPBS) and cell culture reagents were
from Whittaker M.A. Bioproducts (Walkersville, MD). Casein was
from Sigma Chemical Co. (St. Louis, MO), and silicon oil was from
Hüls America (Bristol, PA). Balb/c mice were purchased from
Jackson Laboratory (Bar Harbor, ME).
cDNA Cloning of Mouse LXA4 Receptor. A mouse spleen cDNA
library was purchased from Clontech (Palo Alto, CA), and 6 3
105 clones were screened with the EcoRI fragment from the hu-
man LXA4R cDNA employing high stringency. A positive clone
(designated 15-2) was isolated. Phage DNA was amplified and
purified, and the insert cDNA was excised by EcoRI digestion
and subcloned into the EcoRI site of pBluescript II KS(1) (ob-
tained from Stratagene, La Jolla, CA). Sequence analysis showed
that this clone 15-2 was a partial clone lacking the amino terminal
region (nucleotide 87, of full-length clone; see Fig. 1). To obtain
the missing amino-terminal region, we used the rapid amplifica-
tion of cDNA end or rapid amplification of cDNA end (RACE)
technique. The 59-RACE-Ready cDNAÔ from spleen was pur-
chased from Clontech (Palo Alto, CA), and RACE was performed
according to the manufacturer’s instructions. The first round of
PCR was done between the anchor primer provided by the man-
ufacturer and synthetic primer 59-GCCATTTCAACAAGAAG-
GAATGGTAGAG-39 (antisense of nucleotide 229–257) for 30
cycles (948C for 30 s, 608C for 45 s, 728C for 2 min). The first
PCR product was diluted to 1:50, and a second round of PCR
was carried out between the anchor primer and a synthetic
primer 59-GCTGTGAAAGAGAAGTCAGCCAATGCTA-39
(antisense of nucleotide 199–227) using the same condition for 35
cycles. A PCR product of z300 bp was obtained and subcloned
into pBluescript II KS(1) for sequencing. Overlapping regions of
RACE product and clone 15-2 (nucleotide 87–198) were found
to be identical. The RACE product was subcloned to the 59 end1695 Takano et al.
of clone 15-2 to construct a full-length clone, using a SpeI site at
nucleotide 136. Hydrophobicity analysis of amino acid sequence
and homology comparison were performed using Lasergene
(DNASTAR Inc., Madison WI).
Confirmation of the Mouse PMN Receptor Sequence. The sequence
of the murine LXA4R clone from the spleen library was con-
firmed by RT-PCR of RNA obtained from isolated mouse neu-
trophils. In brief, for isolation of mouse neutrophils, 2 ml of 2%
casein solution was injected into the peritoneal cavity of 8-wk-old
female Balb/c mice. 4 h later, peritoneal lavages were performed
with DPBS21. Wright-Giemsa staining and light microscopy
showed that z85% of the cells harvested were neutrophils, which
were next taken for centrifugation and extraction of RNA using
TriZol reagent (GIBCO BRL, Gaithersburg, MD) following
manufacturer’s instructions. 0.5 mg RNA was reverse-transcribed
and used as the template for PCR, which was performed with sense
primer 59-CAGCTGGTTGTGCAGACAAAATG-39 (correspond-
ing to nucleotide 220 to 3) and antisense primer 59-CATCCCA-
CAGCCCCCTCCTCA-39 (corresponding to nucleotide 1054–
1074), for 25 cycles (948C for 30 s, 648C for 45 s, 728C for 80 s).
The PCR product was subcloned into pBluescript II KS(1) and
five isolated independent clones were sequenced for confirma-
tion; each was found to be identical.
Binding Characteristics of [3H]LXA4 to Chinese Hamster Ovary
Cells Transfected with Mouse LXA4R cDNA. The coding region
of mouse LXA4R was subcloned into mammalian expression vec-
tor pcDNA3 (Invitrogen, San Diego, CA). This plasmid was trans-
fected into Chinese hamster ovary (CHO) cells by the DEAE-dex-
tran method, and after 48 h a binding experiment of [3H]LXA4
was performed as in Fiore et al. (6). Cells were harvested in
DPBS22 (5 mM EDTA), washed twice in DPBS21, and adjusted
to 106 cells/ml. For time course experiments, cells were incu-
bated with 0.3 nM of [3H]LXA4 in the presence or absence of
300 nM unlabeled LXA4 at 48C for the indicated times. For fur-
ther analysis, cells were incubated with 0.3 nM of [3H]LXA4 in the
presence of increasing concentrations of the homoligand LXA4
for 5 min. Reactions were terminated by rapid centrifugation
(12,000 g, 60 s) through silicon oil (d 5 1.028), and cell-associ-
ated radioactivity was determined by liquid scintillation counting.
Specific binding was obtained by subtracting nonspecific binding in
the presence of 3 log order excess of unlabeled LXA4 from each
count, and 106 cells were used per each point. Data were analyzed
with the Ligand program (Biosoft Elsevier, Cambridge, U.K.).
Establishment of Stable Transformant of the Mouse LXA4R. Mouse
LXA4R cDNA in mammalian expression vector pcDNA3 was
also used to establish a CHO cell line stably expressing the mouse
LXA4R (i.e., mouse LXA4R stable transformant). Mouse LXA4R
cDNA and vector alone, namely, pcDNA3 (used as a mock con-
trol), were transfected into CHO-K1 cells by electroporation,
and transformants were selected under the existence of 1g/l G418
for z2 wk. Expression levels of mouse LXA4R mRNA of indi-
vidual colonies were examined by northern hybridization, using
mouse LXA4R cDNA as a probe.
Ligand Operated Guanosine Triphosphate. Guanosine triphosphate
activity was determined in mouse LXA4R stable transformant as
in Fiore et al. (6) with slight modification. Reactions were termi-
nated at 3 min and the rate of GTP hydrolysis was calculated be-
tween time zero and 3 min.
Northern Hybridization of Mouse and Human Multiple Tissue
Blot. Mouse Multiple Tissue Northern BlotÔ including 2 mg
each poly(A)1 RNA of heart, brain, spleen, lung, liver, skeletal mus-
cle, kidney, and testis was purchased from Clontech (Palo Alto, CA).
Mouse neutrophils were isolated by casein-induced peritonitis, as
described in “Confirmation of the mouse PMN receptor se-
quence” (above). Cells were then pelleted by centrifuge, and RNA
was extracted using TriZol reagent (GIBCO BRL) following manu-
facturer’s instructions. 10 mg total RNA was separated by gel elec-
trophoresis in 1% agarose gel containing 1.9% formaldehyde and
blotted to nylon membrane. BamHI–PstI fragment of mouse LXA4
receptor (nucleotide 78–966) was labeled with a-[32P]dCTP us-
ing an oligolabeling kit (Pharmacia, Piscataway, NJ), and hybrid-
ization was performed following the protocol of Church and Gil-
bert in 1% BSA, 7% SDS, 0.5 M phosphate buffer (pH 6.8), 1 mM
EDTA (24), followed by washing in wash buffer A (0.5% BSA,
5% SDS, 40 mM phosphate buffer, pH 6.8, 1 mM EDTA) twice
for 20 min at 658C, and then in wash buffer B (1% SDS, 40 mM
phosphate buffer, pH 6.8, 1 mM EDTA) four times for 20 min at
658C. Filters were exposed to x-ray film with intensifying screen
at 2708C for 72 h (neutrophil) or 120 h (multiple tissue blot).
The human multiple tissue blot was also purchased from Clon-
tech, and northern hybridization was performed as with mouse,
using EcoRI fragment of human LXA4R cDNA as a probe, and
exposed to the x-ray film for 24 h.
Competitive Displacement of [3H]LXA4 and [3H]LTD4 Binding by
15-epi-LXA4 and LXA4 Analogues. Human PMN were isolated
by dextran sedimentation followed by Ficoll gradient separation,
and resuspended in DPBS21 (20 3 106/ml) as in Fiore et al. (18).
Human umbilical endothelial cells (HUVEC) were cultured in a
gelatin-coated (1%) 12-well plate (3.5 3 105/well). PMN and
HUVEC were incubated with [3H]LXA4 (0.3 nM, 5 min at 48C)
and [3H]LTD4 (5 nM, 90 min at 48C), respectively, in the pres-
ence or absence of the increasing concentrations of LXA4 (3–300
nM), LTD4 (5–500 nM) and the indicated LXA4 analogues (20–
2,000 nM). After incubations, cell associated label was separated
from free label by silicon oil method (PMN, see above) or wash-
ing (HUVEC) as in Fiore et al. (18).
Ear Inflammation Model. Ear inflammation was induced as de-
scribed by Ekerdt and Müller (25) with the following minor
modifications. Balb/c mice (8–10 wk old, female) were anesthe-
tized with intraperitoneal injection of pentobarbital (60 mg/kg).
20 ml of acetone was applied to the inner side of the right ear, and
indicated amount of each test compound (i.e., LXA4 analogues or
dexamethasone) suspended in 20 ml acetone was applied to the
inner side of the left ear. Approximately 7 min later, LTB4 (5 mg
in 20 ml of acetone) was applied to both ears. At the indicated
times, mice were euthanized with an overdose of pentobarbital,
and a 6-mm diam of ear sample was obtained from each ear using
a skin biopsy punch. Ear skin samples were used for myeloperox-
idase assay following the method of Bradley et al. (26). In brief,
samples were homogenized in potassium phosphate buffer (pH 6.0)
containing 0.5% hexadecyltrimethylammonium bromide, soni-
cated, and freeze-thawed three times, after which sonication was
repeated. The suspension was centrifuged at 16,000 g for 20 min,
and 100 ml of supernatant was added to 900 ml of potassium phos-
phate buffer (pH 6.0) containing 0.167 mg/ml o-dianisidine dihy-
drochloride (Sigma) and 0.0006% hydrogen peroxide (American
Bioanalytical, Natick, MA). Changes in OD were monitored at
460 nm at 258C, at 30- and 90-s intervals. Isolated mouse neutro-
phils obtained from casein-induced peritonitis (as in preceding sec-
tions) were processed in the same manner and used to obtain a cali-
bration curve for neutrophils, which were enumerated by light
microscopy.
Histological Evaluation of Mouse Ear Skin. Skin samples were ob-
tained using a skin biopsy punch and fixed in 10% buffered form-
aldehyde. Samples were then paraffin-embedded, sliced, and stained
with hematoxylin-eosin.1696 Novel 15-epi-LXA4 Analogues Inhibit Neutrophils In Vivo
Statistical Analysis. Statistical analysis was performed using the
Student’s t-test.
Results
Cloning of the Mouse LXA4R. To evaluate the role and
actions of LX and aspirin-triggered LX stable analogues in
vivo, we first sought the identification and distribution of
the murine LXA4 receptor. The mouse LXA4 receptor was
obtained from a mouse spleen cDNA library. Since this ini-
tial clone lacked the amino terminus, a full-length clone was
obtained using rapid amplification of cDNA end (RACE)
technique (see Materials and Methods). The resulting full-
length clone had an open reading frame encoding 351
amino acids (Fig. 1). To confirm this clone obtained by the
RACE technique, we amplified the coding region of mouse
LXA4R by RT-PCR from RNA obtained from isolated
mouse neutrophils. When the PCR product was sequenced,
five independent clones were obtained that were each iden-
tical to the clone isolated from spleen. Therefore, we con-
cluded that this LXA4R cDNA is indeed present not only
in the mouse cDNA spleen library, but it is also in mouse
neutrophils (see also Fig. 5 A).
As expected, hydrophobicity analysis showed the pres-
ence of a putative seven transmembrane domain character-
istic of the G protein–coupled receptor superfamily (27).
The mouse LXA4R has two N-glycosylation sites in NH2-
terminal extracellular domain, which are also conserved in
human LXA4R (6, 28). The carboxyl-terminal or cytoplas-
mic tail of the mouse LXA4R had nine serine or threonine
residues, among which six were also conserved in human
LXA4R (Figs. 1 and 2). The overall homology between
human and mouse LXA4Rs was 76% in nucleotide sequence
and 73% in the deduced amino acid. An especially high ho-
mology was noted in the sixth transmembrane domain and
second intracellular loop (Fig. 2), suggesting important roles
for these regions in ligand recognition and signal transduc-
tion.
Binding Characteristics of Mouse LXA4R. The human LXA4R
Figure 1. Nucleotide and deduced amino acid sequence of the mouse
LXA4R. The mouse LXA4R has an open reading frame encoding 351
amino acids. Putative transmembrane regions (TM) are indicated with
bars, and possible N-glycosylation sites are indicated by an asterisk (*).
These sequence data are available from EMBL/GenBank/DDBJ under
the accession number U78299.
Figure 2. Alignment of human and mouse LXA4R. (A) The amino
acid sequence of human LXA4R was aligned to the mouse homologue.
Their amino acid sequences were 73% identical. The vertical bars indicate
the identical residues. (B) Percentage of identity of each segment is
shown.1697 Takano et al.
displays both specific and stereoselective binding and acti-
vation with LXA4, which is z0.5 nM Kd in human PMN
and z1.7 nM with transfected CHO cells (5, 6, 18). To
test the ability of this mouse LXA4R to bind LXA4, CHO
cells were transfected with mouse LXA4R cDNA and
tested for their ability to specifically bind [3H]LXA4. Mouse
LXA4R showed specific binding to [3H]LXA4. When per-
formed at 48C, the binding saturated after 5 min (data not
shown). Scatchard analysis gave a Kd of 1.5 6 0.6 nM, which
was obtained with four separate concentrations of unlabeled
LXA4 (mean 6 SEM, n 5 4), a value similar to that of the
human receptor (Kd 1.7 nM) (6), suggesting that this mouse
clone encodes the high-affinity LXA4 receptor (Fig. 3).
Mouse LXA4R Stable Transformant. Next, we established
a stable transformant of the mouse LXA4R to further evalu-
ate the ability of mouse LXA4R to transmit signals. One
clone (designated P4-5) had the highest mRNA expression
of mouse LXA4R when examined by northern hybridiza-
tion (data not shown). To test whether this mouse LXA4R
transmits signal when exposed to LXA4, we examined GTP
hydrolysis activity using this stable cell line P4-5. Treat-
ment of CHO cells expressing human LXA4R with LXA4
stimulates GTPase activation (see reference 6). Upon expo-
sure to 1028 M LXA4, the mouse LXA4R stable transfor-
mant activated GTPase approximately twofold when com-
pared to vehicle alone (vehicle 0.07 6 0.01 vs. LXA4 0.15 6
0.03 pmol/min/106 cells, mean 6 SEM, n 5 5, P ,0.05).
This stimulation was stereoselective because, when tested
in parallel, equimolar of the positional isomer of LXA4,
LXB4 did not elicit this activation (vehicle 0.07 6 0.01 vs.
0.06 6 0.01 pmol/106 cells, mean 6 SEM, n 5 5 and 4,
respectively). Mock transfected CHO cells did not respond
to LXA4 (Fig. 4). Thus, we concluded that we have identi-
fied a functional LXA4R of mouse.
Tissue Distribution of Mouse and Human LXA4R by North-
ern Hybridization. To obtain the tissue distribution of mouse
LXA4R mRNA, and compare it to that of human, north-
ern hybridization of mouse and human multiple tissue blot
was performed (Fig. 5). In mouse, there was one major
band of z1.4 kb with high stringency conditions. LXA4R
mRNA was most abundant in neutrophils, followed by spleen
and lung, organs known to carry contaminants for leukocytes
(Fig. 5 A). When exposed longer (for 14 d), there were
faint bands associated with heart and liver (data not shown).
In humans, we have previously found that LXA4R mRNA
is abundant in lung tissue (6). In the present experiments,
we extended these previous observations and observed that
LXA4R mRNA was also abundant in peripheral leuko-
cytes, followed by spleen (Fig. 5 B). In these two organs, in
addition to a major band of z1.4 kb, another band of z2.4
kb was also observed. In testis, there was a single band of
Figure 3. Specific binding characteristics of mouse LXA4R expressed
in CHO cells. After transfection with mouse LXA4R cDNA (48 h), intact
CHO cells were resuspended in DPBS21 (106 cells /ml). Cells were incu-
bated with 0.3 nM of [3H]LXA4 in the presence of indicated concentra-
tions of homoligand for 5 min at 48C. The incubations were terminated
by rapid centrifugation (12,000 g, 60 s) through silicon oil (d 5 1.028),
and cell-associated radioactivity was determined with 106 cells used per
incubation. Data were analyzed with the Ligand program (Biosoft
Elsevier). Results are representative of four independent experiments
(mean 6 SEM, n 5 4). Specific binding was not detected in the mock
transfected cells with vector (pcDNA3) alone.
Figure 4. GTP hydrolysis by the mouse LXA4R stable transformant.
Rates of g-[32P]dCTP hydrolysis were determined by calculating the lin-
ear regression of 32Pi release in the initial 3 min after ligand addition (1028 M)
to electropermeabilized CHO cells that were stably transfected with
mouse LXA4R cDNA or vector alone. Open bars, mock transfected cells.
Hatched bars, mouse LXA4R stable transformant. Data are mean 6 SEM,
n 5 4–5. *P ,0.05 to all the other bars.1698 Novel 15-epi-LXA4 Analogues Inhibit Neutrophils In Vivo
z1.7 kb, which was not present in mouse. These bands of
different sizes in human suggest the possibility of alternative
splicing in human tissues, but by comparison they are lack-
ing in mouse tissues.
LXA4 and 15-epi-LXA4 Stable Analogues Competitively
Displace [3H]LXA4 Binding. Like other autacoids, LXA4 is
rapidly converted within seconds to minutes in the micro-
environment to inactive LX metabolites, which involves
dehydrogenation at the carbon C-15 position as the pre-
dominant route. To evaluate the action of lipoxins in vivo,
LXA4 stable analogues were designed and prepared by total
organic synthesis, which resist dehydrogenation and v-oxi-
dation, and retain bioactivity (23) (Fig. 6). Both 15(R/S)-
methyl-LXA4 and 15(S)-16-phenoxy-17,18,19, 20-tetra-
nor-LXA4 methyl ester (16-phenoxy-LXA4) were more
resistant to the dehydrogenation by recombinant 15-hy-
droxy prostaglandin dehydrogenase (15-PGDH) than LXA4,
and also resistant to conversion by differentiated HL-60 cells,
and were potent inhibitors of neutrophil transmigration and
adhesion with IC50 ranging from 1–50 nM. 15-epi-LXA4
(carrying a C-15 alcohol in the R configuration), one of
the new eicosanoids triggered by aspirin treatment, also dis-
plays a slower rate of conversion by recombinant enzyme,
suggesting a longer bio-half-life than native LXA4 with its
C-15 alcohol in the S configuration.
With these LXA4 stable analogues in hand, we next ex-
amined whether they compete at the same site as native
LXA4 (Fig. 7 A). [3H]LXA4 binds to its specific receptor on
human neutrophils (18), and therefore in the present study
we used human cells for the purpose of direct comparison
with previous findings (Fig. 7 A). Moreover, it was not
possible to obtain mouse peripheral blood neutrophils in the
amounts that would permit specific binding experiments and
parallel evaluation of each of the synthetic LX analogues.
Each of these bioactive LXA4 analogues competitively dis-
Figure 5. Northern hybridization of the
mouse and human LXA4R. (A) Mouse multi-
ple tissue blot: each lane of mouse multiple
tissue blot contains 2 mg poly(A)1 RNA. 10
mg of total RNA was used for mouse neutro-
phil. Filters were hybridized and washed as
described in Materials and Methods. Filters
were exposed to x-ray film with intensifier at
2808C for 120 h (multiple tissue blot) or 72 h
(neutrophil). (B) Human multiple tissue blot:
each lane contains 2 mg poly(A)1 RNA. Filter
was hybridized and washed as described in
Materials and Methods. Filter was exposed to
x-ray film for 24 h.
Figure 6. Structure of LXA4 stable analogues. Structures of LXA4 sta-
ble analogues used in these experiments. 15-epi-LXA4 is an aspirin trig-
gered lipoxin, and carried a C-15 alcohol at the R configuration, opposite
to the S configuration in native LXA4. 16-phenoxy-LXA4 has phenoxy
group at C-16, and 15-epi-16-phenoxy-LXA4 carried its C-15 alcohol at
the R configuration, in addition to the phenoxy group at C-16, and is a
stable analogue of 15-epi-LXA4. In 15(R/S)-methyl-LXA4, hydrogen at
C-15 was replaced by a methyl group as a racemate at C-15. 15(R/S)-16-
phenoxy-11,12-acetylenic-LXA4 has a phenoxy group at C-16 and race-
mic (z50:50) C-15 alcohol, and also carried an acetylenic bond at C11-12.1699 Takano et al.
placed [3H]LXA4 binding in the following rank order: ho-
moligand LXA4 ø 15-epi-LXA4 .15(R/S)-methyl-LXA4
.16-phenoxy-LXA4. The Ki values for LXA4 in the
present experiments (z2.0 nM) were comparable to the
previously reported values for human neutrophils (18) and
CHO cells expressing human LXA4R (6). Thus, LXA4 stable
analogues compete at the same myeloid receptor as native
LXA4 on human PMN.
LXA4 also carries a vasodilatory action, and is known to
modulate the specific binding of LTD4 on endothelial cells
(21) and glomerular mesangial cells (20). Thus, in addition
to acting at the myeloid LXA4R, LXA4 also competes at a
receptor subtype that also recognizes and responds to the
peptidoleukotriene LTD4. LXA4 also inhibits peptidoleu-
kotriene (LTC4 and LTD4)-induced upregulation of P-selec-
tin in endothelial cells (4). In view of these findings, we ex-
amined whether these LXA4 stable analogues could compete
for [3H]LTD4–specific binding to endothelial cells. As seen
in Fig. 7 B, both native LXA4 and 15-epi-LXA4 competed
with [3H]LTD4 as effectively as the homoligand LTD4 and the
well-characterized LTD4 receptor antagonist SKF-104353.
The LX stable analogues 15-(R/S)-methyl-LXA4 and 16-
phenoxy-LXA4 each gave Ki values within the same range
as the LTD4 antagonist SKF-104353. These results suggest
that these LXA4 stable analogues and 15-epi-LXA4 recog-
nize the same receptors present on both neutrophils and
endothelial cells as LXA4.
LXA4 and 15-epi-LXA4 Analogues Inhibit Mouse Ear In-
flammation. LXA4 inhibits neutrophil adhesion and trans-
migration in vitro (4), and causes downregulation of CD11b/
CD18 on human neutrophils (5). To evaluate this potential
anti-inflammatory action of LXA4 and test whether these
compounds do indeed carry this action in established in
vivo models, we induced skin inflammation in mouse ears
and examined the impact of several new LXA4 stable ana-
logues. After topical application of LTB4 on mouse ear,
time-dependent increase of myeloperoxidase (MPO) activ-
ity in ear skin was observed (Fig. 8, A–C). Since MPO is
well established as a marker of neutrophil infiltration (26),
we calibrated the degree of MPO activity and the number
of neutrophils using standard curves obtained from neutro-
phils isolated after peritoneal lavage (Fig. 8 A). At equimo-
lar concentrations neither FMLP nor platelet-activating
factor induced PMN infiltration when applied topically in
acetone (Fig. 8 A). In contrast to the chemotactic ability of
LTB4, the same amounts of LTD4 did not stimulate neu-
trophil infiltration into this tissue (Fig. 8 B).
Applied alone to the ear, 16-phenoxy-LXA4 had no di-
rect effect on neutrophil infiltration (0–8 h; Fig. 8 B). Also,
no neutrophil influx was noted at intervals up to 48 h (not
shown). When mouse ears were exposed to 16-phenoxy-
LXA4 just before the application of LTB4, neutrophil infil-
tration was markedly attenuated at each time point and the
percent inhibition observed at 24 h was z85% (Fig. 8 C).
Hematoxylin-eosin staining of ear biopsies confirmed these
results and established that 16-phenoxy-LXA4 applied alone
did not alter the tissue architecture (Fig. 9). Ears exposed to
LTB4 exhibited prominent PMN infiltration in perivascular
regions (B), and this PMN infiltration was markedly atten-
uated when the ear was exposed to topical 16-phenoxy-
LXA4 (Fig. 9 C).
The inhibitory action of 16-phenoxy-LXA4 was concen-
tration-dependent (Fig. 8 D), and an IC50 was estimated to
be z120 nmol/cm2. When its potency was directly com-
pared in the same model to a known anti-inflammatory
agent, dexamethasone, 16-phenoxy-LXA4 was as potent as
dexamethasone at the equivalent concentrations (Fig. 8 D).
In the case of native LXA4, its stereoisomer 15-epi-
LXA4, which is generated with aspirin treatment, carries its
C-15 alcohol in the R configuration and is known to be
more potent than native LXA4 in vitro (12). To address the
importance of chirality at C-15 position in vivo, we pre-
Figure 7. Competitive displace-
ment of [3H]LXA4 and [3H]LTD4
by LXA4 analogues. (A) Specific
binding of [3H]LXA4 on PMN:
comparison of 15(R/S)-methyl-
LXA4, 16-phenoxy-LXA4 and 15-
epi-LXA4. PMN were suspended
in DPBS (5 3 107cells/ml) and
binding of [3H]LXA4 (0.3 nM)
was determined at 48C in the
presence or absence of LXA4 (n),
15(R/S)-methyl-LXA4 (s), 15-
epi-LXA4 (l), and 16-phenoxy-
LXA4 (
 
s ) as described in Mate-
rials and Methods. Result is the
representative of three indepen-
dent experiments with duplicate
determination. (B) Evaluation of
LXA4 analogues in [3H]LTD4 dis-
placement assays with HUVEC.
Cells were cultured in 12-wells
plate (z3.5 3 105 cells/well), and [3H]LTD4 (5 nM) binding was assessed at 48C in the presence or absence of unlabeled LTD4 (
 
n ), LXA4(n), 15(R/S)-
methyl-LXA4 (s), 15-epi-LXA4 (l), 16-phenoxy-LXA4 (
 
s ) or SKF-104353 (t) as described in Materials and Methods. Results are the mean 6 SEM
of three separate experiments with duplicate determinations.1700 Novel 15-epi-LXA4 Analogues Inhibit Neutrophils In Vivo
pared and examined the actions of 15-epi-16-phenoxy-LXA4
that carries its C-15 alcohol in the R configuration. This
analogue, like 16-phenoxy-LXA4, was designed to resist in-
activation (23) and is an analogue of the aspirin-triggered
15-epi-LXA4 from this series of LXA4 mimetics (see Fig. 6
for structure). 15-epi-phenoxy-LXA4 was as potent as, or
more potent than, 16-phenoxy-LXA4 (Fig. 8 E), a finding
that supports the notion that the R configuration at the
C-15 position augments the inhibitory actions of LXA4 (23).
When the acetylenic racemate 15(R/S)-16-phenoxy-11,12-
acetylenic-LXA4 (see Fig. 6) was examined in this model, it
showed much less anti-inflammatory action than did either
of the tetraene-containing compounds (i.e., 16-phenoxy-
LXA4 or 15-epi-16-phenoxy-LXA4), suggesting that the loss
of tetraene configuration abrogates bioactivity of these ana-
logues (Fig. 8 E). Thus, LXA4 and aspirin-triggered 15-epi-
Figure 8. Topical application of LXA4 and 15-epi-LXA4 analogues inhibit neutrophil infiltration in vivo. (A) Mouse ears were topically treated with
equimolar amounts of LTB4 (1 mg), FMLP (1.3 mg), or platelet-activating factor (1.6 mg) in 20 ml of acetone. After 24 h, punch biopsy samples (6-mm
diam) were obtained from each ear, and MPO activity was measured as described in Materials and Methods. MPO activity was further converted into
number of neutrophils using the standard curve obtained using peritoneal neutrophils (inset). Neutrophils (2 3 106 cells) gave an absorbance change of
0.25 units per min at 460 nm. Results are mean 6 SEM of n 5 3–5. (B) Mouse ears were topically treated either with vehicle (acetone), 16-phenoxy-
LXA4 (240 nmol), LTB4 (5 mg), or LTD4 (5 mg). After 8 h, PMN infiltration was determined as in Fig. 8 A. Results are mean 6 SEM of n 5 4 (vehicle,
LTB4), n 5 3 (LTD4), or n 5 2 (16-phenoxy-LXA4). (C) Mouse ears were topically treated with either vehicle (s) or 16-phenoxy-LXA4 (240 nmol) (d)
and then exposed to 5 mg LTB4 (see Materials and Methods). Results are mean 6 SEM of n 5 4. *P ,0.01; #, P ,0.05 vs. 16-phenoxy-LXA4 treat-
ment. (D) Mouse ears were topically treated either with vehicle or indicated amount of 16-phenoxy-LXA4 or dexamethasone and then stimulated by 5
mg LTB4 for 8 h. Percent inhibition of PMN infiltration was calculated with vehicle treated ear as 100% after background levels (MPO activity of ear
treated with acetone alone) were subtracted. Results are mean 6 SEM of n 5 3 or 4. (E) Mouse ears were topically treated either with vehicle or 15(R/S)-
16-phenoxy-11,12-acetylenic-LXA4 (120 nmol), or 16-phenoxy-LXA4 (240 nmol), or 15-epi-16-phenoxy-LXA4 (240 nmol), and then exposed to
LTB4 (5 mg) for 8 h. Percent inhibition of PMN infiltration was calculated as in D. (Results for 16-phenoxy-LXA4 are the same in D.) Results are
mean 6 SEM of n 5 3–6.1701 Takano et al.
Figure 9. Ear biopsies: inhibition of LTB4-induced neutrophil infiltra-
tion by 16-phenoxy-LXA4. (A) Section of ear exposed to vehicle alone (8 h).
(B) sections of ears exposed to LTB4 (5 mg) for 8 h as in Fig. 8, upper
panel, low power field; bottom panel, high power. Arrow indicates pres-
ence of neutrophils. (C) Ears exposed to 16-phenoxy-LXA4 and LTB4 as
in Fig. 8; upper panel, low power field and bottom, high power field
showing a sharp reduction in neutrophils. Sections were prepared as de-
scribed in Materials and Methods and stained with hematoxylin and eosin.
LXA4 stable analogues have anti-inflammatory actions in
the mouse ear inflammation model as exemplified by inhi-
bition of neutrophil infiltration, and this bioaction was ste-
reoselective.
Discussion
The present results demonstrate, for the first time, clon-
ing of the mouse myeloid LXA4R and an anti-inflamma-
tory action for both LXA4 and novel aspirin-triggered LXA4
stable analogues in vivo, namely, that topical application of
these analogues and association with the murine receptor
inhibits neutrophil infiltration in skin. The mouse LXA4R
isolated from a spleen cDNA library had a characteristic se-
quence of seven transmembrane spanning G protein–cou-
pled receptors (27), and its homology to the human LXA4R
(6) was 73% in amino acid (Figs. 1 and 2). Mouse LXA4R
gave high-affinity binding to [3H]LXA4 (Kd 1.5 nM), with
values similar to those obtained with the human LXA4R1702 Novel 15-epi-LXA4 Analogues Inhibit Neutrophils In Vivo
(1.7 nM) expressed in CHO cells (6) (Fig. 3). CHO cells
stably transfected with mouse LXA4R and exposed to
LXA4 selectively hydrolyzed GTP, indicating that LXA4
stimulates functional coupling of LXA4R and G protein
(Fig. 4). Tissue distribution of mouse LXA4R mRNA par-
alleled the appearance of human LXA4R mRNA, and this
mRNA was most abundant in mouse neutrophils, followed
by spleen and lung (Fig. 5). Bioactive LXA4 stable ana-
logues effectively displaced both [3H]LXA4 and [3H]LTD4
binding to human neutrophils and endothelial cells, respec-
tively (Fig. 7), results that are consistent with those ob-
tained with native LXA4 (18, 21). These LXA4 analogues
inhibited neutrophil infiltration in the mouse ear inflamma-
tion model, and the level of inhibition was as potent as the
well established anti-inflammatory steroid, dexamethasone
(Fig. 8). The inhibitory actions of LXA4 stable analogues were
stereoselective, with the R epimer (i.e., 15-epi-16-phe-
noxy-LXA4: aspirin-triggered 15-epi-LXA4 analogue) show-
ing a trend for greater potency in this model (Fig. 8).
Of interest, in the phylogenetic tree, mouse and human
LXA4R belong to the chemokine receptor family, rather
than having an association with other eicosanoids such as
the family of prostanoid receptors (29). The leukotriene re-
ceptors remain to be identified at the molecular level. The
chemokine receptor group also includes both the Fusin re-
ceptor and RANTES receptor, which have recently been
shown to serve as cofactors for HIV-I infection (30, 31).
LXA4 is generated during HIV infection at least in vitro
(32), but whether there is a connection between these and
the present results with LXA4 actions remains to be deter-
mined.
The results presented here are also the first direct dem-
onstration of the ability of both LXA4 and novel aspirin-
triggered LXA4 stable analogues to inhibit neutrophil migra-
tion in vivo. 16-phenoxy-LXA4, which resists enzymatic
degradation and is a potent inhibitor of neutrophil adhesion
and transmigration in vitro (23), applied topically to mouse
ear skin just before induction of inflammation clearly
blocks neutrophil infiltration in a concentration-dependent
fashion. LXA4 analogue-induced inhibition of neutrophil
infiltration into the ear skin was as potent as topical applica-
tions of dexamethasone and required the tetraene structure,
since the 11,12-acetylenic-containing analogue was essen-
tially not effective within this concentration range (Fig. 8).
It is of particular interest to point out that other eicosanoid
stable analogues such as the analogue of PGI2, Iloprost, sig-
nificantly enhance LTB4-induced leukocyte infiltration in
this mouse ear model (25). Thus the inhibitory actions of
LXA4 and 15-epi-LXA4 stable analogues established here
for the first time in an in vivo model provide evidence for
the ability of LXA4 to block neutrophil migration, which
appears to be a unique action of lipoxins when compared
to other eicosanoids that either initiate (i.e., LTB4) or en-
hance (PGE2, PGI2) this response in vivo (9, 25).
These inhibitory actions of LXA4 and 15-epi-LXA4 ana-
logues are not likely to be the result of blocking LTB4 bind-
ing to its receptor on neutrophils, because LXA4 does not
compete for the specific binding of [3H]LTB4 (48C) to
neutrophils or differentiated HL-60 cells expressing LTB4
receptors (21). One possible cellular basis for this in vivo
inhibitory action of these analogues is the downregulation
of neutrophil CD11b/CD18 as recently demonstrated for
native LXA4 in vitro, which requires the engagement of
LXA4R (5). Since these LXA4 and 15-epi-LXA4 analogues,
which stereoselectively inhibit neutrophil migration, also
effectively displace specific binding of [3H]LXA4 to its mye-
loid receptor on neutrophils (Fig. 7 A), it is highly likely
that these LXA4 analogues interact with the LXA4R in vivo.
This notion is supported by the finding that the mouse re-
ceptor is primarily associated with mouse neutrophils, which
appear to be the target for their in vivo actions (see Re-
sults). To address a possible systemic action of the LX ana-
logues applied topically, we added 15-epi-16-phenoxy-LXA4
to one ear and applied LTB4 to the other (as in Fig. 8). In
this setting the LXA4 analogue did not inhibit LTB4-induced
PMN infiltration (data not shown), suggesting that the ac-
tion of these analogues was local. Along these lines, phar-
macokinetic studies are in progress in this laboratory to de-
sign LX analogues with increased systemic actions. Together
these findings indicate that activation of the LXA4R in vivo
results in an anti-inflammatory outcome counteracting the
actions of proinflammatory signals such as LTB4 in vivo.
Moreover, they provide the first evidence for anti-inflam-
matory seven transmembrane spanning receptors and path-
ways.
Aspirin treatment of various cell types in vitro enhances
native lipoxin production during cell–cell interactions and
triggers the generation of 15-epi-lipoxins by a separate bio-
synthetic pathway (reviewed in reference 8). These novel
lipoxin R epimers appear to mediate some of the beneficial
actions of aspirin, in particular, 15-epi-LXA4, which blocks
neutrophil adhesion to endothelial cells (12). Therefore, it
is of interest that 15-epi-16-phenoxy-LXA4, an analogue
of 15-epi-LXA4, was the most potent inhibitor of neutro-
phil infiltration in vivo of this series of LXA4 and 15-epi-
LXA4 analogues (Figs. 6 and 8 E). Aspirin has both benefi-
cial and deleterious actions in humans. It is possible that
certain of aspirin’s beneficial actions might now be open to
further experimentation using analogues of 15-epi-lipoxins.
Taken together, the present findings provide direct further
evidence that LXA4 and novel aspirin-triggered 15-epi-
LXA4 stable analogues, as well as mouse LXA4R cDNA,
serve as useful tools to investigate the actions and role of
LXA4 and aspirin-triggered 15-epi-LXA4 in vivo.
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